| 彭其斌，赵建农，王鹏程，陈宝智.成人丘脑胶质瘤综合治疗的疗效分析[J].神经损伤功能重建,2018,13(12):622-625 |
| 成人丘脑胶质瘤综合治疗的疗效分析 |
| Analysis of Curative Effect of Comprehensive Treatment of Adult Thalamic Glioma |
| |
| DOI： |
| 中文关键词: 丘脑胶质瘤 神经外科 放疗 替莫唑胺 预后 |
| 英文关键词: thalamic glioma neurosurgery radiotherapy temozolomide prognosis |
| 基金项目: |
|
| 摘要点击次数: 2754 |
| 全文下载次数: 3220 |
| 中文摘要: |
| 目的：比较放疗期间同步化疗、单纯放疗及放疗后持续化疗对成人丘脑胶质瘤的疗效及不同因素对
成人丘脑胶质瘤预后的影响。方法：选取丘脑胶质瘤成人患者33 例，所有患者均接受肿瘤切除，手术后放
疗期间同步化疗22 例，单纯放疗11 例，放疗后继续化疗20 例（其中，放疗期间同步化疗后继续化疗15 例，单
纯放疗后继续化疗5 例）。统计并比较不同组合治疗方案近期疗效，6 个月、1 年、2 年生存率。结果：术后脑
积水5 例，行脑室-腹腔分流术。平均随访（18.62±5.32）个月，全组平均生存时间（17.40±6.71）个月；6 个月、1
年、2 年总生存率分别为81.82%、69.70%和48.48%。单因素分析显示，丘脑胶质瘤患者总体生存率的影响因
素包括WHO分级（P＜0.05），病程长短（P＜0.05），是否放疗期间同步化疗（P＜0.05）。多因素分析显示病理
WHO分级低、病程短、放疗期间同步化疗的丘脑胶质瘤患者预后较好（P＜0.05）。结论：病理WHO分级、病
程及是否放疗期间同步化疗是成人丘脑胶质瘤预后的主要影响因素，放疗期间同步化疗治疗成人丘脑胶质
瘤疗效明显优于单纯放疗，而放疗后是否持续化疗未显示出明显差异。 |
| 英文摘要: |
| To compare the efficacy of continuous chemotherapy with simultaneous radiotherapy
and radiotherapy alone and continuous chemotherapy after radiotherapy on adult thalamic glioma and the
influence of different factors on the prognosis of adult thalamic glioma. Methods: For this study, 33 adult
patients diagnosed with thalamic glioma were selected. All patients underwent tumor resection; 22 patients
underwent synchronous chemotherapy during radiotherapy after surgery; 11 patients underwent radiotherapy
alone after surgery; 20 patients were treated with continuous chemotherapy after radiotherapy (of these, 15
patients underwent continuous chemotherapy after synchronous chemotherapy during radiotherapy and 5 patients
underwent continuous chemotherapy after radiotherapy alone). The efficacy of different combinations of
treatment regimens and the patient survival rate at 6 months, 1 year, and 2 years were analyzed and compared.
Results: After resection surgery, 5 patients experienced postoperative hydrocephalus, and ventriculoperitoneal
shunting was employed for treatment. The average follow-up time was (18.62±5.32) months. Of all patients, the
median survival period was (17.40 ± 6.71) months. The 6-month, 1-, and 2-year overall survival rate was
respectively 81.82%, 69.70%, and 48.48%. Univariate analysis displayed that the factors that affect overall
survival rate of patients with thalamic glioma include WHO grade (P<0.05), duration of disease (P<0.05), and
synchronous radiotherapy (P<0.05). Multivariate analysis showed that patients with low WHO grade, short
disease course, and concurrent chemoradiotherapy received better prognoses (P<0.05). Conclusion:
Pathological WHO grade, course of disease, and synchronous chemotherapy during radiotherapy are the main
factors affecting the prognosis of adult thalamic gliomas. Synchronous radiotherapy is superior to radiotherapy
alone in the treatment of adult thalamic gliomas, and whether continuous chemotherapy is utlized after
radiotherapy shows no significant difference. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|